Promising treatment options emerging for higher-risk MDS & the value of clinical trials

Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD, King’s College Hospital NHS Foundation Trust, London, UK, comments on the changing landscape of treatment options for patients with higher-risk myelodysplastic syndromes (HR-MDS). Dr Krishnamurthy notes the low response rates of azacitidine monotherapy, which is currently the standard-of-care for these patient groups, and discusses further therapies under evaluation, such as venetoclax plus azacitidine, CPX-351, and magrolimab. To conclude, Dr Krishnamurthy explains the importance of enrolling patients in clinical trials and lists organizations supporting patients in search of these trials. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.